Bidean

BIDEA LLC develops a point-of-care (POC) in-vitro diagnostic device for early endometrial cancer detection. This medical technology provides rapid, accurate screening, employing unlabeled, real-time biosensing to deliver preclinical diagnoses. The approach significantly enhances the efficiency and accessibility of critical health screening, moving beyond traditional invasive procedures.

Founded in May 2016 by scientists Lisandro Cunci and Dr. Carlos R. Cabrera, BIDEA LLC emerged from the insight that late-stage endometrial cancer imposes substantial burdens. Their expertise drives the creation of a non-invasive, faster, and affordable diagnostic tool. The founders aim to reduce healthcare costs and improve patient outcomes through timely intervention.

The product serves gynecologists in hospital and private practices, particularly for women over 50. BIDEA LLC’s vision is to advance women’s health by expanding access to early endometrial cancer screening. They strive to improve patients' quality of life through an innovative Endometrial Cancer Monitoring System offering immediate, accessible screening capabilities.